Angiotensin converting enzyme inhibitors in perspective: an update.
Orally active inhibitors of angiotensin converting enzyme (ACE) have made a major impact on the clinical therapy of hypertension, congestive cardiac failure and ventricular remodelling after myocardial infarction. The ACE inhibitors combine the advantages of efficacy and low incidence of side effects, with the promise of cardio-, vasculo- and reno- protection.
Burrell
L M
LM
Department of Medicine, Austin Hospital, Melbourne, Victoria.
Johnston
C I
CI
D000367:Age Factors; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D003928:Diabetic Nephropathies / Q000188:drug therapy; D004359:Drug Therapy, Combination; D006331:Heart Diseases / Q000188:drug therapy*; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D006977:Hypertension, Renal / Q000188:drug therapy; D006978:Hypertension, Renovascular / Q000188:drug therapy
D000806:Angiotensin-Converting Enzyme Inhibitors